Plegridy - MS Research Australia

Plegridy

Administration Route: Injection
Injection site: SC
Frequency: Fortnightly
TGA approval date: Nov 2014
PBS listed: Yes
Mechanism of action Immunomodulation which is unclear including inhibition of T-cell activation and proliferation; apoptosis of autoreactive T cells; induction of regulatory T cells; inhibition of leukocyte migration across the blood-brain barrier; cytokine modulation; and potential antiviral activity.
%reduction in relapse rate, impact of progression 32% RRR in annual relapes rate, 88% RRR for new Gad Lesions, 78% RRR new T2 lesions, 32% RRR Brain atrophy, 29% RRR disability
Pregnancy Category D
Safe in Pregnancy Suspected to have caused or may be expected to cause, an increased incidence of human fetal malformations or irreversible damage. These drugs may also have adverse pharmacological effects.
Breastfeeding (information predominatly from  LACTMED database) Although no information is available on peginterferon beta-1a in breastmilk, the levels of conventional interferon beta-1a in breastmilk are minuscule. In addition, because interferon is poorly absorbed orally, it is not likely to reach the bloodstream of the infant.
Monitoring requirements Full Blood count, Liver function test (6–12 monthly)
Potential side effects (not a comprehensive list) Injection site reaction. Flu like symptoms, depression, thyroid dysfunction and liver enzyme abnormalities.
Manufacturer Biogen
Contact Us

We're not around right now. But you can send us an email and we'll get back to you, asap.

Start typing and press Enter to search